Taysha Gene Therapies (TSHA) Non-Current Deffered Revenue (2023)
Taysha Gene Therapies (TSHA) posted Non-Current Deffered Revenue of $3.0 million for Q3 2023, down 51.61% sequentially from $6.2 million in Q2 2023.
Powered by 
Analysis
Taysha Gene Therapies (TSHA) Non-Current Deffered Revenue (2023) Analysis & Trends
Taysha Gene Therapies has reported Non-Current Deffered Revenue for 1 years, with the latest figure at $3.0 million in Q3 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 147.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Taysha Gene Therapies | 2.06 Bn | 2.06 Bn | - | - |